SCHEMBL4264458

SCHEMBL4264458

COC(=O)c1cc(-c2ccc(Cl)cc2)ccc1N

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.61
KDM4E B2RXH2 7/20 0.55
MAPT P10636 6/20 0.55
ALDH1A1 P00352 5/20 0.55
HSD17B10 Q99714 3/20 0.55
GAA P10253 3/20 0.55
HPGD P15428 3/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
CASP3 P42574 1/20 0.55
SENP8 Q96LD8 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
SLC6A3 Q01959 4/20 0.54
SLC6A4 P31645 1/20 0.54
CFTR P13569 1/20 0.50
L3MBTL1 Q9Y468 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7529190 0.90 KDM4E (0.66) ABL1KDM4EMAPTALDH1A1HSD17B10
SCHEMBL267531 0.86 ABL1 (0.74) ABL1KDM4EMAPTALDH1A1HSD17B10
SCHEMBL421466 0.85 IKBKB (0.65) ABL1KDM4EMAPTALDH1A1HSD17B10
SCHEMBL29481401 0.84 KDM4E (0.55) ABL1KDM4EMAPTALDH1A1HSD17B10
SCHEMBL1015993 0.84 KDM4E (0.55) ABL1KDM4EMAPTALDH1A1HSD17B10
SCHEMBL11758709 0.83 KDM4E (0.72) ABL1KDM4EMAPTALDH1A1HSD17B10
SCHEMBL29543806 0.83 KDM4E (0.54) ABL1KDM4EMAPTALDH1A1HSD17B10
SCHEMBL21798893 0.83 KDM4E (0.54) ABL1KDM4EMAPTALDH1A1HSD17B10
SCHEMBL7667046 0.82 SLC6A3 (0.55) ABL1KDM4EMAPTALDH1A1NPC1
SCHEMBL5534654 0.81 KDM4E (0.53) ABL1KDM4EMAPTALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8828991-B2 Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments SANOFI (FR) 2014-09-09 US disclosed
US-20090082339-A1 NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS (FR) 2009-03-26 US disclosed
EP-1986646-A1 NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS Sanofi-Aventis (FR) 2008-11-05 EP disclosed
WO-2007093363-A1 NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS (DE) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082339-A1 NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS MCHR1, MPI, TPMT ABL1 281/4885KDM4E 414/4885MAPT 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.